Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells

Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). In NSCLC patients, an EGFR mutation is likely to be correlated with high levels of expressi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Acta Pharmacol Sin
Main Authors: Jiang, Xiao-Ming, Xu, Yu-Lian, Huang, Mu-Yang, Zhang, Le-Le, Su, Min-Xia, Chen, Xiuping, Lu, Jin-Jian
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2017
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5672073/
https://ncbi.nlm.nih.gov/pubmed/28880013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/aps.2017.123
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados